DoPharm is evaluating a takeover of Phaneuf Accelerator Inc. by using the FCF and FCFE valuation approaches. DoPharm has collected the following information for the current year: • Phaneuf has sales...

DoPharm is evaluating a takeover of Phaneuf Accelerator Inc. by using the FCF and FCFE valuation approaches. DoPharm has collected the following information for the current year:
• Phaneuf has sales of $1,000 million with 40% operating margin, depreciation of $90 million, capital expenditures of $170 million, and an increase in working capital of $40 million.
• Interest expenses are $50 million. The current market value of Phaneuf’s outstanding debt is $1,500 million. The company has retired the existing bonds for $10 million.
• FCF and FCFE are expected to grow at 10% for the next five years and 6% after that.
• The tax rate is 30%.
• Phaneuf financed with 40% debt and 60% equity. Its before-tax cost of debt is 9%, and its cost of equity is 13%. The number of shares outstanding is 100 million.

Question: Estimate the current year’s free cash flow of Phaneuf in millions.